Sexual health · 2013
Abacavir exposure and cardiovascular risk factors in HIV-positive patients with coronary heart disease: a retrospective case-control study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Trevillyan Janine M, Cheng Allen C, Hoy Jennifer
Аннотация
BACKGROUND: HIV-positive patients have an estimated twofold increased risk of acute myocardial infarction and coronary heart disease (CHD). While traditional cardiovascular risk factors and the effects of HIV and chronic inflammation all play a role, the contribution of long-term exposure to antiretroviral (ARV) agents is becoming clear.
METHODS: We performed a retrospective case-control study of HIV-positive patients seen from January 1996 to December 2009 to evaluate the impact of HIV suppression and exposure to specific ARVs on the incidence of CHD.
RESULTS: Cases (n=68) were HIV-positive with evidence of CHD. Two age- and sex-matched HIV-positive controls (n=136) without a diagnosis of CHD were assigned for each case. The cumulative incidence of CHD in the period covered by the study was 3.8%, with an incidence of 8.5 cases per 1000 patient-years of follow up. Cases had an increased likelihood of having hypertension (odds ratio (OR): 6.62, P<0.001), a family history of CHD (OR: 5.82, P<0.001), lower high-density lipoprotein levels (OR: 0.28, P=0.025) and higher Framingham risk scores compared with controls. Following adjustment for traditional cardiovascular risk factors, the presence of CHD was significantly associated with the current use of abacavir (OR: 2.10, P=0.03). Protease inhibitor therapy, HIV viral load and duration of known HIV infection were not predictive of CHD in our patient population.
CONCLUSIONS: Our data add to the evidence that abacavir use is associated with CHD in HIV-positive patients in Australia.
METHODS: We performed a retrospective case-control study of HIV-positive patients seen from January 1996 to December 2009 to evaluate the impact of HIV suppression and exposure to specific ARVs on the incidence of CHD.
RESULTS: Cases (n=68) were HIV-positive with evidence of CHD. Two age- and sex-matched HIV-positive controls (n=136) without a diagnosis of CHD were assigned for each case. The cumulative incidence of CHD in the period covered by the study was 3.8%, with an incidence of 8.5 cases per 1000 patient-years of follow up. Cases had an increased likelihood of having hypertension (odds ratio (OR): 6.62, P<0.001), a family history of CHD (OR: 5.82, P<0.001), lower high-density lipoprotein levels (OR: 0.28, P=0.025) and higher Framingham risk scores compared with controls. Following adjustment for traditional cardiovascular risk factors, the presence of CHD was significantly associated with the current use of abacavir (OR: 2.10, P=0.03). Protease inhibitor therapy, HIV viral load and duration of known HIV infection were not predictive of CHD in our patient population.
CONCLUSIONS: Our data add to the evidence that abacavir use is associated with CHD in HIV-positive patients in Australia.